Life Edit Therapeutics
David Wiley, PhD, currently serves as Associate Director at Life Edit Therapeutics since October 2022. Prior to this role, David was a Senior Scientist at Prime Medicine, Inc., where significant advancements in pooled screening platforms were achieved, leading to numerous patents. David's experience includes being a Research Scientist II at Vertex Pharmaceuticals, focusing on flow cytometry-based assays and CRISPR pool screens, and receiving multiple accolades for collaborative achievements. David's early career involved a Postdoctoral Fellowship at Boston Children's Hospital/Harvard Medical School, where crucial insights into the Thyroid hormone pathway and globin switching were developed under the mentorship of Dr. Leonard Zon. David holds a PhD in Cell, Molecular, and Developmental Biology from the University of North Carolina at Chapel Hill and was awarded a Bachelor of Science in Genetics and Cell Biology from The University of Georgia.
This person is not in any offices
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.